Giuseppe Curigliano, President Elect of ESMO and Member of the Editorial Board at OncoDaily, shared a post on LinkedIn:
“The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care.”
Title: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Authors: Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, Sara Lonardi, Simone Scagnoli, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Chiara Cremolini, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri
Read the Full Article.
